Browse EX-10 agreements

FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT

THIS FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”), is made as of June 29, 2026 by and between Tenax Therapeutics, Inc., a Delaware corporation, with its principal place of business in North Carolina (the “Company”), and Christopher Thomas Giordano (the “Executive”). The Company and Executive are sometimes referred to herein each as a “Party” and collectively as the “Parties.”

W I T N E S S E T H:

WHEREAS, the Company and the Executive previously entered into that certain Executive Employment Agreement dated on or about July 6, 2021, whereby the Company employed the Executive as its Chief Executive Officer (the “Employment Agreement”);

WHEREAS, the Company and the Executive wish to amend the Employment Agreement pursuant to this Amendment; and

WHEREAS, the Parties expressly intend that this Amendment shall be a writing intended to be an amendment, modification and/or supplement to the Employment Agreement.

…

AMENDMENT NO. 1 TO NINTH AMENDED AND RESTATED CREDIT AGREEMENT

 

AMENDMENT NO. 1 TO NINTH AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) dated as of June 29, 2026, by and among GCI, LLC (the “Borrower”), the Subsidiary Guarantors, Ventures Holdco, LLC, Credit Agricole Corporate and Investment Bank, as administrative agent (in such capacity, the “Administrative Agent”), the 2026 Incremental Term A-1 Lender (as defined below), the 2026 Incremental Term A-2 Lender (as defined below), the 2026 Incremental Revolving Lender (as defined below) and the 2026 Incremental Issuing Bank (as defined below).

 

W I T N E S S E T H :

 

WHEREAS, the Borrower, the Lenders from time to time party thereto and the Administrative Agent, among others, are parties to that certain Ninth Amended and Restated Credit Agreement, dated as of March 25, 2025 (as amended, restated, supplemented or otherwise modified prior to the date hereof, the “Existing Credit Agreement”);

…

UNITED THERAPEUTICS CORPORATION 2026 STOCK INCENTIVE PLAN

 

(effective June 26, 2026)

  

1.            General

 

(a)            Successor to and Continuation of Prior Plan. This United Therapeutics Corporation 2026 Stock Incentive Plan is intended as the successor to and continuation of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (the “Prior Plan”). From and after the receipt of shareholder approval of this Plan on June 26, 2026 (the “Effective Date”), no additional awards may be granted under the Prior Plan. All awards granted under the Prior Plan will remain subject to the terms of the Prior Plan.

…

Document

Exhibit 10.1

EXECUTION VERSION

ASSIGNMENT, ASSUMPTION AND TERMINATION AGREEMENT

This ASSIGNMENT, ASSUMPTION AND TERMINATION AGREEMENT (this "Agreement"), dated as of June 25, 2026 is made and entered into by and among MediaAlpha, Inc., a Delaware corporation (the "Purchaser"), and each of Insignia QL Holdings, LLC, a Delaware limited liability company, and Insignia A QL Holdings, LLC, a Delaware limited liability company (each, a "Seller" and collectively, the "Sellers"). Capitalized terms that are used but not defined in this Agreement have the meanings specified in that certain Tax Receivable Agreement, dated as of October 27, 2020 (as amended, the "TRA"), by and among the Purchaser, QL Holdings LLC, the Sellers and certain other parties thereto, as amended by First Amendment to Tax Receivables Agreement, dated as of October 1, 2023, by and among the Purchaser, White Mountains Insurance Group, LTD, Tony Broglio and Tigran Sinanyan.

W I T N E S S E T H:

…

Document

Exhibit 10.1

TWELFTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT

TWELFTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) dated as of June 24, 2026, among MERITAGE HOMES CORPORATION, a Maryland corporation (the “Borrower”), MIZUHO BANK, LTD., as assignee from JPMorgan Chase Bank, N.A., as administrative agent on behalf of the Lenders (in such capacity, together with its successors and assigns in such capacity, the “Administrative Agent”), and the Lenders party hereto.

RECITALS:

…

Execution Version

$750,000,000

USD Revolving Facility

$250,000,000

Multicurrency Revolving Facility

 

 

CREDIT AGREEMENT

among

MIDERA FOOD PROCESSING, INC., as Company

ALKAR HOLDINGS, INC., as Initial Borrower

CERTAIN OTHER SUBSIDIARIES OF COMPANY

FROM TIME TO TIME PARTY HERETO,

as Other Borrowers,

BANK OF AMERICA, N.A.

as Administrative Agent

and

VARIOUS LENDING INSTITUTIONS

Dated as of June 29, 2026

 

 

BANK OF AMERICA, N.A.,

COOPERATIEVE RABOBANK U.A., NEW YORK BRANCH,

JPMORGAN CHASE BANK, N.A.,

PNC CAPITAL MARKETS LLC and

WELLS FARGO BANK, NATIONAL ASSOCIATION

as Lead Arrangers and Bookrunners

COOPERATIEVE RABOBANK U.A., JPMORGAN CHASE BANK, N.A., PNC BANK, NATIONAL ASSOCIATION and WELLS FARGO BANK, NATIONAL ASSOCIATION

as Syndication Agents

ING BANK N.V., DUBLIN BRANCH, KEYBANK NATIONAL ASSOCIATION

and TD BANK, N.A.

as Co-Documentation Agents

and

BANK OF AMERICA, N.A.,

as Initial Issuing Bank

 

---

…

Execution Version

 

AMENDED & RESTATED EXPENSE SUPPORT AND CONDITIONAL REIMBURSEMENT AGREEMENT

 

This Amended and Restated Expense Support and Conditional Reimbursement Agreement (the “Agreement”) is made this June 29, 2026, and effective as of May 2, 2026 (the “Effective Date”), by and between PennantPark Private Income Fund, a Delaware statutory trust (the “Company”), and PennantPark Private Income Fund Advisers LLC, a Delaware limited liability company (the “Investment Adviser”).

 

WHEREAS, the Company is a non-diversified, closed-end management investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended (the “Investment Company Act”);

 

WHEREAS, the Company has retained the Investment Adviser to furnish investment advisory services to the Company on the terms and conditions set forth in the amended and restated investment advisory management agreement, dated October 29, 2025, entered between the Company and the Investment Adviser (the “Investment Advisory Management Agreement”);

…

Spousal Consent Letter

I, KOO HYE YOUNG (passport/identity document number: M78224115), am the lawful spouse of Chang Gil LEE. I hereby unconditionally and irrevocably consent to Chang Gil LEE’s execution of the following documents (collectively, the “Transaction Documents”) and to the disposition of the equity interests in Beijing Tongsheng Technology Co., Ltd. (the “Domestic Company”) held and registered in the name of Chang Gil LEE in accordance with such documents:

(1)    the Equity Pledge Agreement entered into among Erhua Medical Technology (Changzhou) Co., Ltd. (the “WFOE”), the Domestic Company and all shareholders of the Domestic Company;

(2)    the Exclusive Purchase Option Agreement entered into among the WFOE, the Domestic Company and all shareholders of the Domestic Company; and

(3)    the Power of Attorney Agreement entered into with the WFOE.

…

Equity Pledge Agreement

This Equity Pledge Agreement (this “Agreement”) is entered into as of June 29, 2026 by and among:

Party A: Erhua Medical Technology (Changzhou) Co., Ltd. (the “Pledgee”), a limited liability company duly organized and existing under PRC law, with its registered address at No. 33 Xiangyun Road, Jiangsu Wujin Economic Development Zone, and unified social credit code 91320412MA22J9TA7M;

Party B: Chang Gil LEE (the “Pledgor”), passport/identity document number M76823514;

Party C: Beijing Tongsheng Technology Co., Ltd., a limited liability company duly organized and existing under PRC law, with its registered address at No. 1078, Building 1, No. A1 Pingfang, Hujialou Beili, Chaoyang District, Beijing (cluster registration), and unified social credit code 91110105MABR6BN869.

Whereas

Pledgor holds 100% of the equity interests in Party C. Party C is a domestic company organized under PRC law and has a registered capital of RMB1,000,000.

…

Financial Advisory Engagement Agreement

This Financial Advisory Engagement Agreement (the “Agreement”) is entered into as of June 9, 2026, by and between JIN MEDICAL INTERNATIONAL LTD., an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), and Goldeenridge Ventures Ltd., a company organized under the laws of the British Virgin Islands (“Advisor”).

1. Engagement

The Company hereby engages Advisor to provide financial advisory services in connection with a proposed asset acquisition project (the “Proposed Project”) involving Beijing Tongsheng Technology Co., Ltd., in a stock issuance, asset acquisition, share exchange or another structure as agreed by the relevant parties (the “Transaction”).

As currently contemplated, the Transaction will involve the issuance of Class A ordinary shares of the Company as consideration for assets or equity interests relating to Beijing Tongsheng Technology Co., Ltd..

2. Scope of Services

Advisor will provide financial advisory services to the Company, including but not limited to:

…

Exclusive Purchase Option Agreement

This Exclusive Purchase Option Agreement (this “Agreement”) is entered into as of June 29, 2026 by and among:

Party A: Erhua Medical Technology (Changzhou) Co., Ltd., a limited liability company duly organized and existing under the laws of the People’s Republic of China (“China”), with its registered address at No. 33 Xiangyun Road, Jiangsu Wujin Economic Development Zone, and unified social credit code 91320412MA22J9TA7M;

Party B: Chang Gil LEE, passport/identity document number M76823514;

Party C: Beijing Tongsheng Technology Co., Ltd., a limited liability company duly organized and existing under the laws of China, with its registered address at No. 1078, Building 1, No. A1 Pingfang, Hujialou Beili, Chaoyang District, Beijing (cluster registration), and unified social credit code 91110105MABR6BN869.

Party A, Party B and Party C are hereinafter referred to individually as a “Party” and collectively as the “Parties”.

Whereas

…

Power of Attorney Agreement

This Power of Attorney Agreement (this “Agreement”) is entered into as of June 29, 2026 by and among:

Party A: Erhua Medical Technology (Changzhou) Co., Ltd., a limited liability company duly organized and existing under PRC law, with its registered address at No. 33 Xiangyun Road, Jiangsu Wujin Economic Development Zone, and unified social credit code 91320412MA22J9TA7M;

Party B: Chang Gil LEE, passport/identity document number M76823514;

Party C: Beijing Tongsheng Technology Co., Ltd., a limited liability company duly organized and existing under PRC law, with its registered address at No. 1078, Building 1, No. A1 Pingfang, Hujialou Beili, Chaoyang District, Beijing (cluster registration), and unified social credit code 91110105MABR6BN869.

Party A, Party B and Party C are hereinafter referred to individually as a “Party” and collectively as the “Parties”.

As of the date hereof, Party C has registered capital of RMB1,000,000, and Party B holds 100% of the equity interests in Party C.

…